Residual β-cell function is a key factor in achieving optimal glycemic control in patients with diabetes, Glucagon stimulation test (GST) is secure and reliable to evaluate β-cell function, but is difficult to be examined in usual clinical settings. While F-CPR-index (Fasting C-peptide (CPR) [ng/ml] / glucose[mg/dl] x100) is widely used as a surrogate marker of insulin secretion. We hypothesized postprandial CPR to glucose ratio (P-CPR-index) can be another efficient marker for evaluating β-cell function in patients with type 2 diabetes (T2DM).Five hundred of Japanese T2DM patients with inadequate glycemic control (HbA1c>7.0) were eligible in this study. HbA1c, fasting CPR and glucose, postprandial (120 min after breakfast) CPR and glucose were measured, and then F-CPR-index and P-CPR-index were calculated. GST was performed as follows: 1mg of glucagon was injected intravenously, CPR was determined before and 6 min after injection, GSTΔCPR (CPR [6 min] - CPR [0 min]) was calculated. Factors correlated with GSTΔCPR were analyzed using simple and multiple stepwise regression analysis. P value<0.05 was defined as statistical difference.Average F-CPR-index, P-CPR-index and GSTΔCPR were 1.60<u>+</u>0.95, 2.67<u>+</u>1.92 and 1.93<u>+</u>1.21, respectively. Simple regression analysis showed that GSTΔCPR was significantly correlated with urinary CPR, F-CPR-index and P-CPR-index as well as age, height, body weight (BW), BMI, waist circumference, duration of diabetes, retinopathy, insulin therapy. Multiple stepwise regression analysis revealed that independent factors contributing to GSTΔCPR were P-CPR-index (β= 0.432), BW (β= 0.336), duration of diabetes (β= -0.107), presence of retinopathy (β= -0.121), use of DPP-4i (β= -0.099), metformin (β= -0.109), SGLT2i (β= -0.108, p= 0.002) but not F-CPR-index.Our date suggested that P-CPR-index was valuable and simple method in assessing residual beta-cell function in daily clinical practice.

Disclosure

T. Abe: None. Y. Matsuhashi: None. T. Fujita: None. S. Chikazawa: None. Y. Fujita: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.